Buy ADB-FUBINACA Online

Description

Buy ADB-FUBINACA Online

Buy ADB-FUBINACA Online, ADB-FUBINACA is a study chemical that functions like a potent agonist for that cannabinoid receptors which first is discovered in 2013 in Japan. Also, the enantiomer of the substance was initially produced by Pfizer in ’09 being an analgesic medication, but never was went after for human use.

Buy ADB-FUBINACA Online,  Moreover, ADB-FUMINACA has the capacity to, dose-dependently, decrease body’s temperature and heartbeat at doses of 3 mg. Lastly, One dying through coronary arterial thrombosis continues to associate with ADB-FUBINACA intoxication. In addition, ADB-FUBINACA is orally active when dissolved inside a fat, which could boost the duration considerably.

Buy ADB-FUBINACA Online,  ADB-FUBINACA powder is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.

Buy ADB-FUBINACA Online An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively.

Buy ADB-FUBINACA Online,   is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs fromby the replacement of the isopropyl group with a tert-butyl group.

Buy ADB-FUBINACA Online, ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively.